← Back to Alkem Laboratories Ltd. overview
Alkem Laboratories Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹12,805 cr | ₹2,165 cr | ₹181.11 | ₹17,691 cr | ₹11,985 cr | 18.07% | 19.56% | 0.12x | 16.91% |
| FY2024 | ₹12,439 cr | ₹1,796 cr | ₹150.19 | ₹15,575 cr | ₹10,312 cr | 17.41% | 18.06% | 0.14x | 14.44% |
| FY2023 | ₹11,440 cr | ₹984 cr | ₹82.31 | ₹13,757 cr | ₹9,045 cr | 10.88% | 13.39% | 0.15x | 8.6% |
| FY2022 | ₹10,512 cr | ₹1,646 cr | ₹137.63 | ₹14,069 cr | ₹8,638 cr | 19.05% | 16.67% | 0.31x | 15.65% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.